Celyad SA (CYAD): Price and Financial Metrics


Celyad SA (CYAD): $2.10

0.01 (+0.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CYAD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CYAD Stock Price Chart Interactive Chart >

Price chart for CYAD

CYAD Price/Volume Stats

Current price $2.10 52-week high $6.40
Prev. close $2.09 52-week low $1.51
Day low $2.10 Volume 2,100
Day high $2.16 Avg. volume 12,983
50-day MA $2.10 Dividend yield N/A
200-day MA $3.45 Market Cap 33.80M

Celyad SA (CYAD) Company Bio


Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.


CYAD Latest News Stream


Event/Time News Detail
Loading, please wait...

CYAD Latest Social Stream


Loading social stream, please wait...

View Full CYAD Social Stream

Latest CYAD News From Around the Web

Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.

Celyad Oncology Announces February 2022 Conference Schedule

MONT-SAINT-GUIBERT, Belgium, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in February 2022: Virtual 11th Annual SVB Leerink Global Healthcare Conference 2022Dates: Monday, February 14 to Friday, February 18, 2022Presentation: F

Yahoo | January 31, 2022

Is CNS Pharmaceuticals, Inc. (CNSP) Outperforming Other Medical Stocks This Year?

Here is how CNS Pharmaceuticals, Inc. (CNSP) and Celyad SA (CYAD) have performed compared to their sector so far this year.

Yahoo | January 20, 2022

Celyad Oncology Provides Outlook for 2022

MONT-SAINT-GUIBERT, Belgium, January 10, 2022--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced a 2021 year-end review and provided an outlook for 2022.

Yahoo | January 10, 2022

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

Yahoo | December 31, 2021

Celyad Oncology SA: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)

MONT-SAINT-GUIBERT, Belgium, December 31, 2021--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the below information following the issuance on 8 December 2021 of 6,500,000 new shares of Celyad Oncology SA (the "Company") to an affiliate of Fortress Investment Group (such affiliate "Fo

Yahoo | December 31, 2021

Read More 'CYAD' Stories Here

CYAD Price Returns

1-mo 0.72%
3-mo -34.78%
6-mo -42.78%
1-year -61.75%
3-year -89.61%
5-year -94.74%
YTD -42.62%
2021 -53.08%
2020 -25.14%
2019 -42.62%
2018 -57.87%
2017 142.68%

Continue Researching CYAD

Want to see what other sources are saying about Celyad Sa's financials and stock price? Try the links below:

Celyad Sa (CYAD) Stock Price | Nasdaq
Celyad Sa (CYAD) Stock Quote, History and News - Yahoo Finance
Celyad Sa (CYAD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4896 seconds.